Furnas B E, Williams S D, Einhorn L H, Cobleigh M A
Cancer Treat Rep. 1982 Sep;66(9):1709-11.
A dose of 3-4 mg/m2 of vindesine (DVA) was given by iv push weekly to 33 patients with non-small cell lung cancer. Twenty-nine patients were evaluable for response. All evaluable patients had a performance status greater than 50% and measurable disease, and received at least two consecutive weekly doses of DVA. Standard response criteria were used. Among 15 patients with squamous cell carcinoma there were four partial responses and one complete response; three of eight patients with adenocarcinoma had partial responses. The overall response rate was 28% (eight responses among 29 patients). Myelosuppression was moderate, but two patients were hospitalized for granulocytopenic infections. The most common dose-limiting side effects were due to neurotoxicity. Four responding patients had treatment stopped because of neurotoxic reactions. DVA appears to be among the most active drugs in non-small cell lung cancer, but improved dose schedules that reduce neurotoxicity would be highly desirable.
对33例非小细胞肺癌患者每周静脉推注长春地辛（DVA），剂量为3 - 4mg/m²。29例患者可评估疗效。所有可评估的患者体能状态均大于50%且有可测量病灶，并接受了至少连续两周的DVA治疗。采用标准疗效标准。15例鳞状细胞癌患者中有4例部分缓解，1例完全缓解；8例腺癌患者中有3例部分缓解。总缓解率为28%（29例患者中有8例缓解）。骨髓抑制为中度，但有2例患者因粒细胞缺乏感染住院。最常见的剂量限制性副作用是神经毒性。4例缓解患者因神经毒性反应而停止治疗。长春地辛似乎是治疗非小细胞肺癌最有效的药物之一，但非常需要改进剂量方案以降低神经毒性。
